Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

November 30, 2024

Conditions
Acute LeukemiaMyelodysplastic SyndromesT-lymphoblastic LymphomaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute Biphenotypic LeukemiaAcute Undifferentiated Leukemia
Interventions
DRUG

Cyclophosphamide

pre-transplant conditioning treatment

DRUG

Fludarabine

pre-transplant conditioning treatment

RADIATION

Total Body Irradiation

pre-transplant conditioning treatment

DRUG

Busulfan

pre-transplant conditioning treatment

DRUG

Mesna

given with cyclophosphamide

DRUG

Sirolimus

post-transplant treatment for GVHD

DRUG

Mycophenolate Mofetil

post-transplant treatment for GVHD

DRUG

Filgrastim

post-transplant treatment for GVHD

DRUG

Cyclophosphamide

post-transplant treatment for GVHD

PROCEDURE

Bone Marrow Transplant

Transplant with investigational bone marrow product

Sponsors
All Listed Sponsors
collaborator

Center for International Blood and Marrow Transplant Research

NETWORK

lead

Ossium Health, Inc.

INDUSTRY

NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | Biotech Hunter | Biotech Hunter